Karuna Therapeutics Inc . (NASDAQ:KRTX) reported Q2 EPS of ($2.17), $0.11 worse than the analyst estimate of ($2.06). Revenue for the quarter came in at $5.28 million.
Karuna Therapeutics Inc . (NASDAQ:KRTX) reported Q2 EPS of ($2.17), $0.11 worse than the analyst estimate of ($2.06). Revenue for the quarter came in at $5.28 million.